SCHEMBL1964244

SCHEMBL1964244

CC(C)(C)n1nc(Cc2ccc(Cl)cc2)c2c(N)ncnc21

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 12/20 0.75
AKT1 P31749 1/20 0.65
KDR P35968 6/20 0.64
ABL1 P00519 4/20 0.64
RIPK2 O43353 3/20 0.64
FYN P06241 3/20 0.64
PRKACA P17612 3/20 0.64
CSNK1A1 P48729 3/20 0.64
MAPK14 Q16539 3/20 0.64
LCK P06239 3/20 0.64
MAPK8 P45983 2/20 0.64
CYP1A2 P05177 2/20 0.64
EGFR P00533 2/20 0.64
YES1 P07947 2/20 0.64
LYN P07948 2/20 0.64
PDGFRA P16234 2/20 0.64
FRK P42685 2/20 0.64
MAPK9 P45984 2/20 0.64
CSNK1D P48730 2/20 0.64
BLK P51451 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1964152 0.89 SRC (0.66) SRCAKT1KDRABL1RIPK2
SCHEMBL13019703 0.88 SRC (0.65) SRCAKT1KDRABL1RIPK2
SCHEMBL409554 0.88 SRC (0.65) SRCAKT1KDRABL1RIPK2
SCHEMBL3785884 0.87 SRC (0.74) SRCAKT1KDRABL1RIPK2
SCHEMBL1961578 0.87 SRC (0.74) SRCAKT1KDRABL1RIPK2
SCHEMBL13063872 0.86 SRC (0.66) SRCAKT1KDRABL1RIPK2
SCHEMBL13019850 0.86 SRC (1.00) SRCAKT1KDRABL1RIPK2
SCHEMBL1961935 0.85 SRC (0.62) SRCAKT1KDRABL1RIPK2
SCHEMBL12551810 0.83 SRC (0.69) SRCAKT1KDRABL1RIPK2
SCHEMBL12551738 0.83 SRC (0.69) SRCAKT1KDRABL1RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12023385-B2 Tunable endogenous protein degradation with heterobifunctional compounds DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-07-02 US disclosed
EP-4119552-A1 REGULATING CHIMERIC ANTIGEN RECEPTORS Dana-Farber Cancer Institute, Inc. (US) 2023-01-18 EP disclosed
US-11311609-B2 Regulating chimeric antigen receptors DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-04-26 US disclosed
US-9512125-B2 Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-12-06 US disclosed
US-9512125-B2 Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-12-06 US disclosed
US-9512125-B2 Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-12-06 US disclosed
US-20110144134-A1 Anti-Inflammatory Pyrazolopyrimndines THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-06-16 US disclosed
US-20110144134-A1 Anti-Inflammatory Pyrazolopyrimndines THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-06-16 US disclosed
US-20110144134-A1 Anti-Inflammatory Pyrazolopyrimndines THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-06-16 US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 US disclosed
US-20090124638-A1 ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-05-14 US disclosed
US-20090124638-A1 ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-05-14 US disclosed
US-20090124638-A1 ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12023385-B2 Tunable endogenous protein degradation with heterobifunctional compounds DBN1, MYCBP, PSMG3 SRC 3905/4885AKT1 4596/4885KDR 4167/4885
US-20110144134-A1 Anti-Inflammatory Pyrazolopyrimndines TSLP, NLRP3, IL1B SRC 3970/4885AKT1 4799/4885KDR 4362/4885
US-11311609-B2 Regulating chimeric antigen receptors NFATC1, TNFRSF9, IL2RA SRC 303/4885AKT1 1695/4885KDR 1516/4885
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING RAB1A, COPB1, GOLT1B SRC 1332/4885AKT1 968/4885KDR 4598/4885
US-20090124638-A1 ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES TNF, TSLP, IL1B SRC 3920/4885AKT1 4779/4885KDR 3813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.